Linkedin
RLS logo_header
Linkedin

Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced

“This is the most encouraging efficacy signal with a non-chemo regimen we have ever seen in anal cancer,” said Jared Kelly, Chief Executive Officer of Oncolytics Biotech. “Achieving a 30% objective response rate — more than double the benchmark of the only approved immunotherapy — along with multiple responses lasting more than a year, including two complete responses, underscores pelareorep’s ability to unlock deep and durable immune responses. We believe the data represent our best chance to obtain an accelerated approval in a rare disease with virtually no options outside of chemotherapy.”

Read the full story on "Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced"

Share:

More News

Patient Treatment Restarted in Ph 2 INVINCIBLE-4 Study of Neoadjuvant INT230-6 in TNBC Patients

“We are excited to have restarted our Phase 2 study in presurgical triple-negative breast cancer. Triple-negative is a deadly and aggressive form of breast cancer, and patients having local disease currently undergo a harsh six-month regimen whereby a small percentage can die from the SOC before their surgery,” said Intensity

Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO

“TRAVERSE represents a potential breakthrough for both Allogene and the broader CAR T field,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene. “CAR T has transformed hematologic malignancies while solid tumors have remained one of the field’s most difficult challenges. When we designed ALLO-316 with the

Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced

“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and

Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported

“As the data continue to mature, we are increasingly encouraged by the preliminary findings emerging from both cohorts, particularly the overall survival trends observed in the cohort with MGMT unmethylated glioblastoma,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “These findings further reinforce our belief that targeting mitochondrial